APA (7th ed.) Citation

NJ, G., CE, M., TK, H., DT, M., A, V. B., J, K., . . . LE, H. (2021). A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. NPJ precision oncology, 5(1), 41. https://doi.org/10.1038/s41698-021-00181-4

Chicago Style (17th ed.) Citation

NJ, Gurule, et al. "A Tyrosine Kinase Inhibitor-induced Interferon Response Positively Associates with Clinical Response in EGFR-mutant Lung Cancer." NPJ Precision Oncology 5, no. 1 (2021): 41. https://doi.org/10.1038/s41698-021-00181-4.

MLA (9th ed.) Citation

NJ, Gurule, et al. "A Tyrosine Kinase Inhibitor-induced Interferon Response Positively Associates with Clinical Response in EGFR-mutant Lung Cancer." NPJ Precision Oncology, vol. 5, no. 1, 2021, p. 41, https://doi.org/10.1038/s41698-021-00181-4.